CTOs on the Move

Promentis Pharmaceuticals

www.promentispharma.com

 
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Promentis Pharmaceuticals raised $26M on 03/30/2017

Similar Companies

biosynexus

Biosynexus understands that bringing a new pharmaceutical product to market is a complicated process that involves not only having strong research and development capabilities, but also having deep clinical development, manufacturing and marketing

Ridgmar Pharmacy

Ridgmar Pharmacy is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Phlow

Securing our nation’s pharmaceuticals through U.S. Manufacturing.

Daiichi Sankyo

Learn about who we are, our approach to scientific innovation, our areas of therapeutic focus, our products, commitments and more.

ASP Global

We help you reach your savings targets and your patient experience goals by designing and delivering supplies and patient care products.